The present invention relates to the antibody combined with human interleukin-2 (hIL-2). The present invention is more particularly to the humanized antibody of the defined epitope of specific binding hIL-2, which shows the unique ability for inhibiting hIL-2 in conjunction with CD25 when combining the epitope.